Tilray Brands (TLRY) Non Operating Investment Income (2019 - 2026)
Tilray Brands (TLRY) reported Non Operating Investment Income of -$4.1 million for Q1 2026, up 24.31% on a YoY basis from -$3.3 million in Q1 2025, and down 1100.87% quarter-over-quarter from -$345000.0 in Q4 2025.
Tilray Brands (TLRY) Non Operating Investment Income (2019 - 2026) Analysis & Trends
Tilray Brands has reported Non Operating Investment Income for 8 years, with the latest figure at -$4.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income rose 24.31% year-over-year to -$4.1 million; the trailing twelve-month figure through Feb 2026 stood at -$10.0 million (down 83.24% YoY), and the FY2022 full-year result was -$6.7 million, down 186.44% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$4.1 million, down from -$345000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $459000.0 in Q4 2023, with the low at -$5.5 million in Q1 2025.
- Historically, Non Operating Investment Income has averaged -$1.4 million across 5 years, with a median of -$596000.0 in 2022.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income soared 177.01% — and 2025, when it sank 16687.88%.
- Tilray Brands' Non Operating Investment Income stood at -$596000.0 in 2022, then surged by 177.01% to $459000.0 in 2023, then tumbled by 92.81% to $33000.0 in 2024, then tumbled by 1145.45% to -$345000.0 in 2025, then tumbled by 1100.87% to -$4.1 million in 2026.
- The last three Non Operating Investment Income figures came in at -$4.1 million (Q1 2026), -$345000.0 (Q4 2025), and -$8000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Tilray Brands | - | - | 54.95 Mn | -4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -4.14 Mn |
| Feb 28, 2026 | -4.14 Mn |
| Nov 30, 2025 | -345,000.00 |
| Nov 30, 2025 | -345,000.00 |
| Aug 31, 2025 | -8,000.00 |
| Aug 31, 2025 | -8,000.00 |
| Feb 28, 2025 | -5.47 Mn |
| Feb 28, 2025 | -5.47 Mn |
| Feb 29, 2024 | 33,000.00 |
| Feb 29, 2024 | 33,000.00 |
| Nov 30, 2023 | 459,000.00 |
| Nov 30, 2023 | 459,000.00 |
| Feb 28, 2023 | -925,000.00 |
| Feb 28, 2023 | -925,000.00 |
| Nov 30, 2022 | -596,000.00 |
| Nov 30, 2022 | -596,000.00 |
| Aug 31, 2022 | -1.01 Mn |
| Aug 31, 2022 | -1.01 Mn |
| May 31, 2022 | 97,000.00 |
| May 31, 2022 | 97,000.00 |